![Donald Mitchell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Donald Mitchell
Plus aucun poste en cours
Historique de carrière de Donald Mitchell
Anciens postes connus de Donald Mitchell
Sociétés | Poste | Début | Fin |
---|---|---|---|
IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | 01/01/2005 | 01/01/2008 |
US Department of the Navy (District of Columbia) | Public Communications Contact | - | - |
SPRING BANK PHARMACEUTICALS, INC. | Directeur des opérations | 01/03/2011 | - |
Corporate Officer/Principal | 01/01/2008 | 01/03/2011 |
Formation de Donald Mitchell
United States Naval Academy | Undergraduate Degree |
University of Virginia Darden School of Business | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
Corporate Officer/Principal | 2 |
Chief Operating Officer | 1 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Government | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
F-Star Therapeutics, Inc. (United States)
![]() F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
Idenix Pharmaceuticals LLC
![]() Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
US Department of the Navy (District of Columbia) | Government |
- Bourse
- Insiders
- Donald Mitchell
- Expérience